Skip to main content
. Author manuscript; available in PMC: 2012 Aug 10.
Published in final edited form as: J Control Release. 2011 May 7;153(3):288–296. doi: 10.1016/j.jconrel.2011.05.005

Fig. 5.

Fig. 5

L-FOA-IRN combination therapy in C26 tumor-bearing mice. Balb/c mice (n=8) were treated with i.v. injections on Days 8 and 15 (as indicated by arrows). A. Anti-tumor activity. Error bars represent SEM. B. Effect of combination therapy on weight of C26 tumor-bearing mice. C and D. Survival curves. The treatment group s are PBS, L-FOA (10 mg/kg; 57.4 μmol/kg), L-IRN (50 mg/kg; 73.8 μmol/kg), L-FOA-IRN 5:1 (5 mg/kg or 28.7 μmol/kg FOA; 3.9 mg/kg or 5.7 μmol/kg IRN), L-FOA + L-IRN 5:1 (5 mg/kg or 28.7 μmol/kg FOA; 3.9 mg/kg or 5.7 μmol/kg IRN), and L-FOA + L-IRN 5:1 double strength (10 mg/kg or 57.4 μmol/kg FOA; 7.8 mg/kg or 11.5 μmol/kg IRN).